[Comment] Safety and immunogenicity of the Hendra virus recombinant soluble glycoprotein G Nipah virus vaccine in adults

Nipah virus (NiV) is a highly pathogenic zoonotic virus that has been responsible for recurrent outbreaks throughout south and southeast Asia with mortality rates ranging from 21% to 82%, making it into the list of WHO priority pathogens.1 Since its discovery in Malaysia in 1999, NiV has posed a serious public health and pandemic threat, particularly due to its potential for human-to-human transmission and the absence of licensed therapeutics or vaccines.2 Since 2001, the outbreaks have been reported in Bangladesh and India.